SCHEMBL751395

SCHEMBL751395

COC(=O)NCC(C)CC(=O)N1CC(C#N)CC1c1ncc(-c2ccc(Br)cc2)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.41
CYP3A4 P08684 4/20 0.41
KCNH2 Q12809 3/20 0.41
NR1I2 O75469 2/20 0.41
ABCB11 O95342 1/20 0.41
OPRK1 P41145 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 1/20 0.38
F11 P03951 4/20 0.36
F2 P00734 1/20 0.36
PRCP P42785 6/20 0.35
HDAC1 Q13547 1/20 0.32
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL749528 0.84 CYP2C9 (0.40) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL748770 0.83 CYP3A4 (0.59) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL751761 0.82 CYP3A4 (0.43) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL2707990 0.82 CYP3A4 (0.61) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL2756969 0.82 CYP3A4 (0.61) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL205945 0.82 CYP3A4 (0.61) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL749345 0.81 CYP3A4 (0.44) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL748939 0.78 MAPK13 (0.39) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL204507 0.78 CYP2C9 (0.43) CYP2C9CYP3A4KCNH2NR1I2ABCB11
SCHEMBL9980233 0.78 CYP2C9 (0.43) CYP2C9CYP3A4KCNH2NR1I2ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2430014-A1 ANTIVIRAL COMPOUNDS Gilead Sciences, Inc. (US) 2012-03-21 EP disclosed
WO-2010132601-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2010-11-18 WO disclosed